QCG
AGIO icon

Quadrant Capital Group’s Agios Pharmaceuticals AGIO Stock Holding History

Quadrant Capital Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16
Closed -$542 – 1272
2026
Q1 		$542 Hold
16
– – ﹤0.01% 2629
2025
Q4 		$436 Hold
16
– – ﹤0.01% 2657
2025
Q3 		$643 Buy
+16
New +$602 ﹤0.01% 2589
2025
Q2 		– Sell
-73
Closed -$2.14K – 1356
2025
Q1 		$2.14K Sell
73
-27
-27% -$896 ﹤0.01% 2500
2024
Q4 		$3.29K Hold
100
– – ﹤0.01% 2409
2024
Q3 		$4.44K Hold
100
– – ﹤0.01% 2346
2024
Q2 		$4.31K Buy
100
+27
+37% +$974 ﹤0.01% 2334
2024
Q1 		$2.13K Sell
73
-13
-15% -$348 ﹤0.01% 2497
2023
Q4 		$1.92K Sell
86
-20
-19% -$448 ﹤0.01% 2481
2023
Q3 		$2.62K Sell
106
-26
-20% -$688 ﹤0.01% 2318
2023
Q2 		$3.74K Buy
132
+46
+53% +$1.15K ﹤0.01% 2278
2023
Q1 		$1.98K Buy
86
+14
+19% +$372 ﹤0.01% 2429
2022
Q4 		$2.02K Sell
72
-309
-81% -$8.71K ﹤0.01% 2415
2022
Q3 		$11K Buy
381
+14
+4% +$376 ﹤0.01% 1823
2022
Q2 		$8K Buy
367
+325
+774% +$7.34K ﹤0.01% 1755
2022
Q1 		$1K Buy
42
+3
+8% +$92 ﹤0.01% 2231
2021
Q4 		$1K Sell
39
-58
-60% -$2.33K ﹤0.01% 2230
2021
Q3 		$4K Buy
97
+11
+13% +$531 ﹤0.01% 1912
2021
Q2 		$5K Hold
86
– – ﹤0.01% 1816
2021
Q1 		$4K Hold
86
– – ﹤0.01% 1840
2020
Q4 		$4K Buy
86
+54
+169% +$2.13K ﹤0.01% 1732
2020
Q3 		$1K Buy
32
+13
+68% +$570 ﹤0.01% 1904
2020
Q2 		$1K Sell
19
-570
-97% -$26.4K ﹤0.01% 2001
2020
Q1 		$21K Buy
589
+115
+24% +$5.31K ﹤0.01% 1247
2019
Q4 		$22K Buy
+474
New +$17.9K ﹤0.01% 1675
2019
Q3 		– Sell
-11
Closed – – 2284
2019
Q2 		$0 Sell
11
-105
-91% -$5.61K ﹤0.01% 2305
2019
Q1 		$7K Buy
+116
New +$6.76K ﹤0.01% 1768
2016
Q1 		– Sell
-16
Closed – – 1794
2015
Q4 		$0 Sell
16
-84
-84% -$5.51K ﹤0.01% 1576
2015
Q3 		$5K Buy
100
+84
+525% +$8.21K ﹤0.01% 803
2015
Q2 		$1K Buy
+16
New +$1.72K ﹤0.01% 1018

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Quadrant Capital Group's AGIO Position: Q2 2026 in Review

Quadrant Capital Group sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 16 shares — an estimated $542 sold.

Quadrant Capital Group first reported a position in AGIO in Q2 2015 and held it in 30 quarters. The position peaked at $22K in Q4 2019. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Quadrant Capital Group reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 16 Agios Pharmaceuticals shares in Q2 2026, an estimated $542.
  • Quadrant Capital Group first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 30 quarters.
  • Quadrant Capital Group's Agios Pharmaceuticals position peaked at $22K in Q4 2019.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.